None listed
Conditions
Interventions
None listed
Sponsors
Jeonbuk National University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Study Group ? Patients with Idiopathic Parkinson’s Disease (Study Group) Adults aged 19 years or older who have been diagnosed with Parkinson’s disease based on the United Kingdom Brain Bank Parkinson’s Disease Criteria Individuals who voluntarily agree to participate in the study and are able to comply with sample collection and other clinical research procedures 2) Healthy Adults (Control Group) Adults aged 19 years or older with no significant neurological disorders, including Parkinson’s disease Individuals without systemic diseases that could affect sample quality or test results Individuals who voluntarily agree to participate in the study and are able to comply with sample collection and other clinical research procedures
Exclusion criteria
Exclusion criteria: 1. Individuals showing a normal binding pattern on presynaptic dopaminergic transporter imaging 2. Individuals with significant neurological disorders that may affect the assessment of Parkinson’s disease (e.g., stroke, severe head trauma, or other chronic neurodegenerative diseases including Parkinson’s disease dementia), or systemic diseases that may significantly impact overall health status (e.g., cancer, autoimmune diseases) 3. Individuals in the study or control group who are expected to have difficulty providing appropriate responses to the study questionnaires 4. Individuals who are currently pregnant or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ? Demographic Information Age, sex, smoking history, alcohol consumption Physical examination: height, weight Personal and medical history of systemic and dermatological diseases (e.g., seborrheic dermatitis, xerosis) Concomitant medications ? Dietary Information, Bowel Habits, and Lifestyle Patterns Assessment of dietary intake Bowel movement characteristics and frequency Daily routine and lifestyle habits ? Parkinson’s Disease–Related Clinical Information and Rating Scales (applicable to PD patient group only): Date of Parkinson’s disease onset and diagnosis, family history of PD, current PD medications Montreal Cognitive Assessment-Korean version (MoCA-K) Korean Non-Motor Symptoms Scale (K-NMSS) Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Parts 2, 3, and 4 Scales for Outcomes in Parkinson’s Disease–Autonomic (Scopa-AUT) REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ) ? Biological Data Collection and Analysis: Microbiota profiling from skin, gut, nasal cavity, and oral cavity, along with blood sample analysis Extraction of genomic DNA (gDNA) from bacterial and fungal communities Target gene amplification for community analysis of bacteria and fungi (16S rRNA variable regions V1–3 and V3–4, ITS1) Sequencing using PacBio or Illumina MiSeq (or HiSeq, NovaSeq) platforms to generate raw data Microbial sequence analysis using established bioinformatic pipelines (QIIME2, DADA2), and functional metagenomic analysis Measurement of a-synuclein and other biomarkers (e.g., tau protein, amyloid) in blood, skin, nasal/oral, and gut samples | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical scale assessments: K-NMSS (Korean version of the Non-Motor Symptoms Scale), MDS-UPDRS (Movement Disorder Society–Unified Parkinson’s Disease Rating Scale);Clinical scale assessments: K-NMSS (Korean version of the Non-Motor Symptoms Scale), MDS-UPDRS (Movement Disorder Society–Unified Parkinson’s Disease Rating Scale) | — |
Countries
Korea, Republic of
Contacts
Public ContactHwang Yun su
Jeonbuk National University Hospital
Outcome results
None listed